Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
NCT ID NCT02812420
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how the drugs affect the immune system and tumor. It is not yet known if this approach improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab and Tremelimumab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new pre-surgery treatment option for bladder cancer patients who cannot tolerate standard chemotherapy.
What could go wrong
This is a very early, small pilot study focused on safety, not effectiveness. The drugs may cause immune-related side effects, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.